Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 10/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665963 | 1.00 | PDE2A (0.34) | PDE2ATSHRGLANPSR1ALDH1A1 | |
| SCHEMBL4669016 | 0.91 | PDE2A (0.35) | PDE2ATSHRGLANPSR1ALDH1A1 | |
| SCHEMBL5806166 | 0.90 | PDE2A (0.35) | PDE2ATSHRGLANPSR1ALDH1A1 | |
| SCHEMBL23943801 | 0.88 | PDE2A (0.36) | PDE2ATSHRGLANPSR1ALDH1A1 | |
| SCHEMBL22818585 | 0.87 | PDE2A (0.33) | PDE2ATSHRGLANPSR1ALDH1A1 | |
| SCHEMBL22800686 | 0.87 | PDE2A (0.33) | PDE2ATSHRGLANPSR1ALDH1A1 | |
| SCHEMBL22800687 | 0.87 | PDE2A (0.33) | PDE2ATSHRGLANPSR1ALDH1A1 | |
| SCHEMBL22800685 | 0.87 | PDE2A (0.33) | PDE2ATSHRGLANPSR1ALDH1A1 | |
| SCHEMBL4665970 | 0.85 | PDE2A (0.37) | PDE2ATSHRGLANPSR1ALDH1A1 | |
| SCHEMBL7821613 | 0.84 | PDE2A (0.38) | PDE2ATSHRGLANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167121-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-01 | — | — | US | disclosed |
| WO-2021211408-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167121-A1 | SUBSTITUTED {1,2,4,} TRIAZOLO{1,5-A} PYRIMIDINE COMPOUNDS AND USE IN STABILIZING MICROTUBULES | MAPT, TUBA4A, MAP4 | PDE2A 3816/4885TSHR 4078/4885GLA 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.